# Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrea Sartore‐Bianchi,Livio Trusolino,Cosimo Martino,Katia Bencardino,Sara Lonardi,Francesca Bergamo,Vittorina Zagonel,Francesco Leone,Ilaria Depetris,Erika Martinelli,Teresa Troiani,Fortunato Ciardiello,Patrizia Racca,Andrea Bertotti,Giulia Siravegna,Valter Torri,Alessio Amatu,Silvia Ghezzi,Giovanna Marrapese,Laura Palmeri,Emanuele Valtorta,Andrea Cassingena,Calogero Lauricella,Angelo Vanzulli,Daniele Regge,Silvio Veronese,Paolo M. Comoglio,Alberto Bardelli,Silvia Marsoni,Salvatore Siena |
| Citations | 1,018 |
| DOI | 10.1016/s1470-2045(16)00150-9 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | http://hdl.handle.net/2318/1560696 |
| OpenAlex ID | https://openalex.org/W2336815607 |
| PMID | 27108243 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Sara Lonardi](https://scholariq.org/researchers/sara-lonardi/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Paper topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Cells and Metastasis](https://scholariq.org/topics/cancer-cells-and-metastasis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.